Castle Biosciences Inc.
Castle Biosciences Inc. (CSTL): 3 pipeline candidates · 2 upcoming catalysts · ~36 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
35.7 months
D/E 0.19 · 0% dilution
Lead: Phase 3
3 candidates
2 upcoming, next in ~4031d
0 buys · 82 sells (180d)
A transparent, data-derived signal for Castle Biosciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$614.2M
Cash
$63.8M
Quarterly Burn
$22.1M
Runway
35.7 mo
Revenue
$83.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| d-fi | Phase 3 |
| esopredict | Preclinical |
| fcx-007 | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
185
Total value held
$633.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,982,946 | $73.2M |
| rtw investments, lp | 2,758,335 | $67.7M |
| vanguard capital management llc | 2,355,044 | $57.8M |
| principal financial group inc | 1,769,877 | $43.5M |
| dimensional fund advisors lp | 1,039,761 | $25.5M |
| summit partners public asset management, llc | 940,685 | $23.1M |
| vanguard portfolio management llc | 861,771 | $21.2M |
| state street corp | 769,079 | $18.9M |
| geode capital management, llc | 728,100 | $17.9M |
| aigh capital management llc | 590,601 | $14.5M |
Showing top 10 of 185 institutional holders of Castle Biosciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Castle Biosciences Inc.'s pipeline?
Castle Biosciences Inc. (CSTL) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Castle Biosciences Inc.'s lead drug candidate?
Castle Biosciences Inc.'s most advanced tracked candidate is d-fi (Phase 3) for Dystrophic Epidermolysis Bullosa.
What is Castle Biosciences Inc.'s next catalyst?
Castle Biosciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Re" — expected July 1, 2037.
What is Castle Biosciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Castle Biosciences Inc. has approximately 35.7 months of cash runway.
What is Castle Biosciences Inc.'s market capitalization?
Castle Biosciences Inc.'s market capitalization is approximately $614.2M.
Get the full picture on Castle Biosciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.